Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBIQV3)

Drug Name

4-Carboxycinnamic Acid Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hemoglobin (HB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voxelotor	DMCS6M5	Sickle-cell disorder	3A51	Approved	[2]
Iron	DMAP8MV	Anemia of prematurity		Approved	[3]
Iron Dextran	DM5OY70	Iron-deficiency anemia	3A00	Approved	[3]
PolyHeme	DMV8EXG	Blood forming organ disorder	JB64.1	Phase 3	[4]
Efaproxyn	DMX7BM4	Lung cancer	2C25.0	Phase 3	[5]
Hemoglobin raffimer	DMMTL7V	Anemia	3A00-3A9Z	Phase 2/3	[6]
GBT021601	DMD3C21	Sickle-cell disorder	3A51	Phase 2/3	[7]
FBS-0701	DMR3952	Iron overload disease	5C64.10	Phase 2	[8]
HQK-1001	DM7QUN0	Beta thalassemia	3A50.2	Phase 2	[9]
5-hydroxymethyl-2-furfural	DMPFVJB	Anemia	3A00-3A9Z	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3	Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
4	Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
5	Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
6	Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
7	GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.
8	A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
9	A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
10	5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.